Pearl Therapeutics Announces Positive Results From Phase 2a Trial of Formoterol Inhalation Aerosol in Chronic Obstructive Pulmonary Disease

-- Company's First Clinical Trial in COPD; Demonstrates
Safety and Efficacy of Formoterol Fumarate Delivered by Pearl's
Proprietary High-Performance Metered Dose Inhaler (MDI) Product
--
REDWOOD CITY, Calif., Jan. 4 /PRNewswire/ -- Pearl...